Premium
Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant
Author(s) -
Okada Seigo,
Azuma Yoshihiro,
Suzuki Yasuo,
Yamada Hiroko,
WakabayashiTakahara Midori,
Korenaga Yuno,
Akase Hideaki,
Hasegawa Shunji,
Ohga Shouichi
Publication year - 2016
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12778
Subject(s) - medicine , kawasaki disease , adjunct , refractory (planetary science) , pediatrics , physics , artery , astrobiology , philosophy , linguistics
Herein we describe the case of a 6‐week‐old boy who developed complete Kawasaki disease (KD). The cytokine profile and activation of monocytes and subsequent T cells matched the typical feature of refractory KD. The patient received a total of three courses of i.v. immunoglobulin (IVIG), but did not achieve clinical relief. Adjunctive therapy with oral cyclosporine A (CsA) led to prompt defervescence. This was continued for 7 days without serious adverse events. Coronary artery dilatations regressed within 3 months of follow up. KD infants <3 months of age are at higher risk of coronary artery aneurysm than the older ones. To our knowledge, oral CsA treatment has not been reported in such young infants with KD. The diagnosis and treatment of very young infants with KD are challenging. Adjunctive use of CsA in IVIG treatment could be effective for refractory KD in infants <3 months of age.